Ventyx Biosciences Inc
VTYX2.300USD
-0.090-3.77%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
163.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ventyx Biosciences Inc Unternehmen
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Unternehmensinformationen
BörsenkürzelVTYX
Name des UnternehmensVentyx Biosciences Inc
IPO-datumOct 21, 2021
CEOMr. Raju Mohan, Ph.D.
Anzahl der mitarbeiter79
WertpapierartOrdinary Share
GeschäftsjahresendeOct 21
Addresse12790 El Camino Real, Suite 200
StadtSAN DIEGO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92130
Telefon18589452393
Websitehttps://ventyxbio.com/
BörsenkürzelVTYX
IPO-datumOct 21, 2021
CEOMr. Raju Mohan, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Roy M. Gonzales
Mr. Roy M. Gonzales
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. William R. White, J.D.
Mr. William R. White, J.D.
Independent Director
Independent Director
--
--
Ms. Onaiza Cadoret - Manier
Ms. Onaiza Cadoret - Manier
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Moore
Mr. Matthew (Matt) Moore
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Point72 Asset Management, L.P.
8.27%
Affinity Asset Advisors LLC
6.36%
New Science Ventures, LLC
5.65%
The Vanguard Group, Inc.
4.43%
Tang Capital Management, LLC
4.35%
Andere
70.94%
Aktionäre
Aktionäre
Anteil
Point72 Asset Management, L.P.
8.27%
Affinity Asset Advisors LLC
6.36%
New Science Ventures, LLC
5.65%
The Vanguard Group, Inc.
4.43%
Tang Capital Management, LLC
4.35%
Andere
70.94%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
29.20%
Investment Advisor/Hedge Fund
15.82%
Investment Advisor
13.55%
Venture Capital
5.88%
Individual Investor
4.11%
Research Firm
4.08%
Family Office
0.27%
Andere
27.08%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
368
54.53M
76.62%
-50.77M
2025Q1
385
51.70M
72.65%
-54.51M
2024Q4
397
65.14M
91.63%
-35.16M
2024Q3
387
62.43M
88.32%
-37.01M
2024Q2
376
67.39M
95.54%
-30.30M
2024Q1
369
70.49M
100.19%
-8.56M
2023Q4
345
54.61M
92.50%
-19.94M
2023Q3
315
66.31M
112.60%
-5.18M
2023Q2
302
65.66M
112.13%
-3.35M
2023Q1
267
64.47M
110.86%
+4.32M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Point72 Asset Management, L.P.
4.23M
5.95%
+2.45M
+137.64%
Mar 31, 2025
Affinity Asset Advisors LLC
4.06M
5.7%
+4.06M
--
May 22, 2025
New Science Ventures, LLC
4.03M
5.67%
-3.07M
-43.23%
Mar 28, 2025
The Vanguard Group, Inc.
3.51M
4.94%
+5.11K
+0.15%
Mar 31, 2025
Tang Capital Management, LLC
3.10M
4.36%
--
--
Mar 31, 2025
Mohan (Raju)
2.30M
3.24%
--
--
Apr 10, 2025
Vestal Point Capital, LP
2.00M
2.81%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.39M
1.96%
-3.09M
-68.91%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
